AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04487275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MLC901 or Placebo
Description: groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months
Study NCT01136759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel
Description: One applicator of tenofovir 1% gel administered vaginally for 7 consecutive days
Study NCT01136759 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: One applicator of placebo gel administered vaginally for 7 consecutive days
Study NCT03611907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oocyte retrieval with only aspiration system SL1(Cook® Single Lumen)
Description: In this intervention a 17-Gauge needle is used to aspirate the follicles
Study NCT03611907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oocyte retrieval with aspiration and flushing system DL1 (Cook® EchoTip® Double Lumen)
Description: In this intervention a 17-Gauge needle is used to aspirate follicle, and consequently a 1 mL flush is injected and aspirated twice for each punctured follicle
Study NCT04227678 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Heparin
Description: an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours, starting 15 minutes before ingestion of liquid meal
Study NCT04227678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: liquid meal
Description: low fat meal: (500 mL, 898 Kcal, 13% fat, 20.3% protein and 62.3% carbohydrates) will be ingested over 20 minutes
Study NCT04529135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
Study NCT04529135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
Study NCT00615199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: administration via oral route twice daily
Study NCT03110172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine Hydrochloride
Description: The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation
Study NCT01791543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intramural Needle Ablation Catheter
Study NCT00266331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reduced glutathione
Study NCT00999453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LDL-cholesterol
Description: This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.
Study NCT00999453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LDL-cholesterol
Description: This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.
Study NCT04462731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical root canal treatment filled with WVT
Description: All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. WVT was used to fill the tooth when the months were January, March, May, July, September, and November.
Study NCT04462731 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical root canal treatment filled with SBT
Description: All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. SBT was used to fill the tooth when the months were February, April, June, August, October, and December.
Study NCT03241134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
Study NCT03241134 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham needling
Description: During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
Study NCT00967473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF® Single-Piece NATURAL Toric IOL Model SN60T9 and Model SN60T8.
Description: ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Model SN60T9 in the first eye and either the ACRYSOF® Single-Piece Toric NATURAL IOL Model SN60T9 or Model SN60T8 in the second eye.
Study NCT03529552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Cruciate Ligament Reconstruction
Description: Placement of an SMS bioresorbable interference screw (DEDIENNE Santé)
Study NCT00303485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium supplementation
Description: As prescribed
Study NCT03023124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Treatment with trabectedin repeated every 21 days for 6 cycles
Study NCT03023124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Treatment with Adriamycin at day 1 every 21 days for 6 cycles
Study NCT03023124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Treatment with Dacarbazine at days 1 and 2 every 21 days for 6 cycles
Study NCT03982069 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist live attenuated influenza vaccine
Description: Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.
Study NCT03982069 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flucelvax inactivated influenza vaccine
Description: Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.
Study NCT03841305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver preparation before major hepatectomy
Description: Simultaneous portal and hepatic vein embolization versus Portal vein embolization, also called venous deprivation OR portal vein embolization.
Study NCT03841305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver preparation before major hepatectomy
Description: Simultaneous portal and hepatic vein embolization versus Portal vein embolization, also called venous deprivation OR portal vein embolization.
Study NCT04342026 — intervention group
Intervention type: OTHER
Intervention: Measure of the exposure of parent of male with /without cryptorchidism to endocrine disruptors
Description: Measure of the exposure of parent of patient with/without cryptorchidism to endocrine disruptors (job exposure, during pregnancy)
Study NCT00303485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D and calcium supplementation
Description: As prescribed
Study NCT00303485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 6 months
Study NCT03896945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules
Study NCT03896945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Description: oral capsules
Study NCT01207752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Balance
Description: Artificial tear emulsion drop
Study NCT01207752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optive Lubricant Eye Drops
Description: Artificial tear eye drop
Study NCT01193114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecologically Based Treatment (EBT)
Description: Substance abuse treatment (the Community Reinforcement Approach), case management and housing.
Study NCT01193114 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment/intervention as normally provided by community service agencies that service substance abusing homeless families.
Study NCT00856726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-34 parathyroid infusion
Description: 1-34 parathyroid infusion at 0.055 mcg/kg/hr for 6 hours
Study NCT03594136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raumedic Neurovent-P-tel
Description: Insertion of a Neurovent-P-tel in adults to study normal intracranial pressure
Study NCT02649894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Approved Uncoated PleurX Indwelling Pleural Catheter
Study NCT02649894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)
Study NCT03666689 — intervention group
Intervention type: PROCEDURE
Intervention: surgical technique
Description: surgical reconstruction
Study NCT00643331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise performed at gym and at home comprising strength, balance and impact exercise
Study NCT01813136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous pazopanib (Arm A)
Description: Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
Study NCT00973323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 2.5mg bid
Study NCT00973323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 5mg bid
Study NCT01813136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent pazopanib (Arm B)
Description: Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression
Study NCT00973323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 10mg bid
Study NCT00973323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose-adjusted warfarin based on target INR values
Study NCT02843503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterialized-venous reference (YSI)
Description: All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. The samples will be arterialized using a heated-hand-box (arterialized-venous reference (YSI). Blood will be drawn for the determination of glucose concentrations using arterialized-venous sampling techniques per YSI.
Study NCT02843503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous reference measurement (YSI)
Description: All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. Blood will be drawn for the determination of glucose concentrations using venous sampling techniques measured per YSI.
Study NCT02843503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capillary reference (SMBG)
Description: All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive vingerstick measurements to sample capillary blood measured per Self Monitoring of Blood Glucose (SMBG) device.
Study NCT02905669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFLIP
Description: Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device
Study NCT04916912 — intervention group
Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting
Description: Coronary artery bypass surgery is a surgical procedure to restore normal blood flow to an obstructed or stenotic coronary artery.
Study NCT02812719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycolic acid peel alone
Description: One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals
Study NCT02812719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycolic and salicylic acid peel
Description: The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals.
Study NCT01616680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given IV
Study NCT01616680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01616680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02431078 — intervention group
Intervention type: PROCEDURE
Intervention: Routine comprehensive treatment
Description: Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy
Study NCT01963845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Study NCT01963845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03482037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rec 0/0438 1 mg or Rec 0/0438 2 mg
Description: Each vial content will be administered via the catheter used for the self-catheterization
Study NCT03482037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Each vial content will be administered via the catheter used for the self-catheterization
Study NCT01357551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance intervention
Description: Theoretically-informed maintenance intervention that involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
Study NCT01073384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGX201 (delayed release beclomethasone 17,21-dipropionate)
Description: Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy.
Study NCT01237600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cultivated limbal transplantation
Description: Cultivated corneal epithelial stem cell transplantation. Autograft, Living related allograft, and Cadaveric allograft
Study NCT02998658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal cuff closure using barbed sutures
Description: Vaginal cuff will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA )
Study NCT00615199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration via oral route twice daily
Study NCT00147459 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBV vaccine booster
Study NCT03197441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Intraoperative platelet-rich plasma injection during arthroscopic knee surgery
Study NCT02735109 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: photographies
Description: cells description by taken photographies vith confocal microscope (VivaScope 3000)
Study NCT02735109 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: biopsy normal area
Description: biopsy done to compare with abnormal area
Study NCT01315431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel plus capecitabine
Description: Study medication, which will include tesetaxel capsules and capecitabine tablets, will be administered orally for two 21-day cycles. In each cycle, tesetaxel will be administered at a dose of 27 mg/m2 on Day 1, and capecitabine will be administered in Cohort 1 at a dose of 2000 mg/m2/day and in Cohort 2 at a dose of 1750 mg/m2/day (in 2 equally divided doses) on Day 1 through Day 14.~At the conclusion of Cycle 2, patients who, in the opinion of the investigator, appear to have benefitted from protocol therapy may receive up to 6 additional cycles under a separate protocol.
Study NCT02203357 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.
Study NCT02203357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.
Study NCT01288963 — intervention group
Intervention type: DRUG
Intervention: IL-2
Description: Observation only